KUALA LUMPUR: Hong Seng Consolidated Bhd‘s healthcare arm HS Bio Sdn Bhd has signed a collaboration settlement with Mediven Innovation Ventures Sdn Bhd to broaden their respective protection within the healthcare sector.
Mediven is a gaggle of firms concerned within the healthcare sector and has approvals, licenses accreditations
Shifting ahead, HS Bio and Mediven will collectively discover alternatives and markets for his or her respective merchandise and will collectively pursue tenders and bids for initiatives by offering a extra complete vary of options.
“The collaboration with Mediven represents a brand new alternative for HS Bio to broaden into one more essential part in healthcare which is the manufacturing of medical gadgets.
“We discover that Mediven’s confirmed high quality in internationally-recognised assessments, in addition to its success in executing initiatives and exporting their merchandise, will definitely lend us an amazing hand in bidding for brand spanking new initiatives and gaining publicity in abroad markets,” Hong Seng government director and HS Bio director Christopher Chan mentioned in a press release.
In the meantime, Mediven operations director Dr Lim Li Sze mentioned: “Mediven is happy to be part of this new partnership which can additional broaden its attain and vary of choices within the healthcare sector.”
“We consider that by combining our strengths as a number one molecular diagnostics supplier in Malaysia with HS Bio’s wide-reaching healthcare provide chain options, each events will have the ability to make a big impression in bettering well being and stopping infectious ailments.
“That is aligned with Mediven’s imaginative and prescient to ship high quality medical diagnostics quicker and higher, regionally and globally,” Lim mentioned.